



## Biophysical evidence for differential gallated green tea catechins binding to membrane type-1 matrix metalloproteinase and its interactors



Djahida Djerir<sup>a</sup>, Mustapha Iddir<sup>a</sup>, Steve Bourgault<sup>b</sup>, Sylvie Lamy<sup>a</sup>, Borhane Annabi<sup>a,b,\*</sup>


<sup>a</sup> Laboratoire d'Oncologie Moléculaire, Centre de recherche BIOMED, Université du Québec à Montréal, Québec H3C 3P8, Canada

<sup>b</sup> Centre de recherche Pharmaqam, Département de Chimie, Université du Québec à Montréal, Québec H3C 3P8, Canada

### HIGHLIGHTS

- Multiple tumorigenic processes involve membrane type-1 matrix metalloproteinase.
- Disease prevention properties of tea have been attributed to catechins.
- Surface plasmon resonance was used to assess catechins binding to MT1-MMP.
- Gallated catechins have higher affinity towards MT1-MMP and its interactors.

### GRAPHICAL ABSTRACT



### ARTICLE INFO

#### Keywords:

Catechins  
Polyphenols  
MT1-MMP  
Surface plasmon resonance  
Green tea

### ABSTRACT

Membrane type-1 matrix metalloproteinase (MT1-MMP) is a transmembrane MMP which triggers intracellular signaling and regulates extracellular matrix proteolysis, two functions that are critical for tumor-associated angiogenesis and inflammation. While green tea catechins, particularly epigallocatechin gallate (EGCG), are considered very effective in preventing MT1-MMP-mediated functions, lack of structure-function studies and evidence regarding their direct interaction with MT1-MMP-mediated biological activities remain. Here, we assessed the impact in both cellular and biophysical assays of four ungallated catechins along with their gallated counterparts on MT1-MMP-mediated functions and molecular binding partners. Concanavalin-A (ConA) was used to trigger MT1-MMP-mediated proMMP-2 activation, expression of MT1-MMP and of endoplasmic reticulum stress biomarker GRP78 in U87 glioblastoma cells. We found that ConA-mediated MT1-MMP induction was inhibited by EGCG and catechin gallate (CG), that GRP78 induction was inhibited by EGCG, CG, and gallocatechin gallate (GCG), whereas proMMP-2 activation was inhibited by EGCG and GCG. Surface plasmon resonance was used to assess direct interaction between catechins and MT1-MMP interactors. We found that gallated catechins interacted better than their ungallated analogs with MT1-MMP as well as with MT1-MMP binding partners MMP-2, TIMP-2, MTCBP-1 and LRP1-clusterIV. Overall, current structure-function evidence supports a role for the galloyl moiety in both direct and indirect interactions of green tea catechins with MT1-MMP-mediated oncogenic processes.

**Abbreviations:** C, catechin; CNS, central nervous system; ConA, concanavalin-A; EC, epicatechin; ECM, extracellular matrix; EGC, epigallocatechin; EGCG, epigallocatechin gallate; GBM, glioblastoma; 67LR, 67 kDa laminin receptor; LRP-1, low-density-lipoprotein receptor-related protein-1; MMP-2, metalloproteinase-2; MT1-MMP, membrane type-1 matrix metalloproteinase; MTCBP-1, MT1-MMP cytoplasmic tail-binding protein-1; SPR, surface plasmon resonance; TIMP-2, tissue inhibitor of metalloproteinase-2; TLR, Toll-like receptor

\* Corresponding author at: Laboratoire d'Oncologie Moléculaire, Université du Québec à Montréal, C.P. 8888, Succ. Centre-ville, Montréal, Québec H3C 3P8, Canada.

E-mail address: [annabi.borhane@uqam.ca](mailto:annabi.borhane@uqam.ca) (B. Annabi).

<https://doi.org/10.1016/j.bpc.2018.01.002>

Received 1 December 2017; Received in revised form 11 January 2018; Accepted 12 January 2018

Available online 31 January 2018


0301-4622/ © 2018 Elsevier B.V. All rights reserved.

## 1. Introduction


The use of various natural phytochemicals and dietary compounds in cancer chemoprevention is believed to prevent the onset of pathophysiological processes which regulate tumor growth [1]. Furthermore, epidemiological and pre-clinical data, obtained through *in vitro* and *in vivo* animal studies, support the concept that these compounds can downregulate oncogenic signaling pathways or sensitize malignant cells to cytotoxic agents [2]. Unfortunately, only a limited number of these compounds have been tested in clinical trials often because of the lack of structure-function molecular evidence supporting their capacity to interact with their cellular targets and to interfere with the associated biological processes [3].

Among natural polyphenolic compounds, prophylactic and therapeutic properties have been attributed to green tea catechins and black tea theaflavins [4]. In fact, among tea polyphenols which possess potent

antioxidant and anti-inflammatory properties that modulate signaling pathways [5], epigallocatechin-3-gallate (EGCG) is one of the most studied active substances and considered to act through diversified molecular mechanisms [6]. Its *in vitro* cellular effects were documented in numerous central nervous system (CNS) cancer cell models including glioblastoma [7–9], pediatric brain tumor-derived medulloblastoma [10], and in childhood primitive neuroectodermal brain tumors [11]. Interestingly, combining EGCG with Temozolomide [12] or to ionizing radiation [13, 14] was found to enhance therapeutic efficacy. Among the molecular processes targeted by EGCG, inhibition of cell proliferation, survival, *in vitro* endothelial cell tubulogenesis, pro-inflammatory intracellular transducing events, as well as cell migration/invasion processes have been reported [15, 16]. In addition, EGCG was recently documented to alter the membrane bound matrix metalloproteinase MT1-MMP functions in cancer cell invasion and survival processes through the inhibition of its capacity to hydrolyze extracellular matrix



**Fig. 1.** Scheme of MT1-MMP predicted interactors and molecular structure of green tea-derived catechins. A) STRING V10.0 algorithm was used to identify MT1-MMP protein-protein interactors (<http://string-db.org/>). LRP-1, Low density lipoprotein receptor-related protein 1, MT1-MMP, membrane type-1 matrix metalloproteinase; MMP-2, matrix metalloproteinase-2, MTCBP-1, MT1-MMP cytoplasmic tail-binding protein-1; TIMP, tissue inhibitor of matrix metalloproteinase. Chemical structures of B) ungalated catechins, and C) equivalent galated catechins which were used in cellular and acellular assays. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)



**Fig. 2.** Impact of catechins on Concanavalin-A-induced MT1-MMP expression in U87 glioblastoma cells. Serum-starved U87 glioblastoma cells were treated with 30  $\mu\text{g/ml}$  ConA for 24 h in the presence of 30  $\mu\text{M}$  of each of either the ungalloylated catechins (C, GC, EC, EGC) or with equivalent galloylated catechins (CG, GCG, ECG, EGCG). Lysates were harvested upon treatment and immunoblots performed for A) MT1-MMP and C) GRP78 as described in the [Materials and methods](#) section. Scanning densitometry was used to quantify the extent of ConA-mediated B) MT1-MMP and D) GRP78 inductions.

(ECM) components [17], to activate latent proMMP [18], and to signal pro-angiogenic and pro-inflammatory intracellular events involving Erk, RhoA/ROK, Src or JAK/STAT3 pathways [8, 19, 20].

While evidence suggests that the effects of EGCG are, in part, mediated through its specific interaction with the 67 kDa laminin receptor (67LR) [21], the molecular mechanism of action of the other catechins remains mostly unknown. Interestingly, interaction studies of catechins with the 67LR has led to the conclusion that catechin (C), epicatechin (EC), and epigallocatechin (EGC) were unable to bind to the 67LR [21]. Unfortunately, much less information was provided about the galloylated catechins. It is yet unknown whether EGCG's structural analogs, that also contain the galloyl moiety, bind to the same EGCG receptor. Initial structure-function studies have suggested galloyl moiety of catechins to inhibit phorbol ester-induced MMP-9 and HuR expressions [22], as well as to dictate fatty-acid synthase inhibition [23]. More recently, *in silico* molecular docking analysis predicted EGCG and epicatechin-3-gallate (ECG) mode of binding to MT1-MMP and proMMP-2/MMP-2 [24], as well as to proMMP-9/MMP-9 [25]. However, these studies were conducted at supraphysiological millimolar concentrations of catechins and did not assess the ability of catechins to alter MT1-MMP's intracellular signaling capacities. Whether physiological plasmatic concentrations of any of these catechins allow direct binding and interaction with MT1-MMP itself or interactors of MT1-MMP has not been documented yet.

In the current study, we used surface plasmon resonance (SPR) and compared the potential direct interaction of four ungalloylated green tea-derived catechins to their galloylated equivalents towards either MT1-MMP itself, to several predicted interactors such as matrix metalloproteinase-2 (MMP-2), tissue inhibitor of metalloproteinases (TIMP)-2, MT1-MMP cytoplasmic tail-binding protein-1 (MTCBP-1), or to MT1-MMP cell surface substrates such as the low-density-lipoprotein receptor-related protein-1 (LRP-1). Structure-function cellular assays were also performed at physiological plasmatic catechin concentrations to address MT1-MMP-dependent processes involved in proMMP-2 activation and in GRP78 endoplasmic reticulum stress induction within

ConA-activated U87 glioblastoma cells.


## 2. Results

### 2.1. MT1-MMP interactors and structure of several green tea-derived catechins

MT1-MMP possesses extracellular hydrolytic activities as well as intracellular cell transducing functions in brain tumorigenesis [26]. Among the principal molecular interactors predicted using the STRING protein-protein interaction database [27], MT1-MMP, proMMP-2 (MMP-2) and TIMP-2 were confirmed and are well known to contribute to the formation of the ternary complex required for optimal processing of latent proMMP-2 into active MMP-2 (Fig. 1A) [28]. TIMP-1 was also identified (not shown) but is known to weakly interact with MT1-MMP [29, 30]. The cell surface low density lipoprotein-related protein 1 (LRP1), as well as the intracellular partners Furin and MTCBP-1 are believed to interact with the cytoplasmic domain of MT1-MMP, which interaction could possibly modulate MT1-MMP's signal transducing functions [31]. In order to document the possible structure-function interactions of catechins with these predicted interactors, the structure of four ungalloylated catechins (Fig. 1B) as well as of four galloylated equivalent catechins (Fig. 1C) were first tested on known cellular conditions which require MT1-MMP functions.

### 2.2. Cellular impact of catechins on Concanavalin-A-induced expressions of MT1-MMP and GRP78, and on the activation of proMMP-2

Despite the evidence supporting green tea catechins possess chemopreventive and anti-inflammatory properties [32], structure-function studies remain scarce. We decided to treat serum-starved U87 glioblastoma cells with Concanavalin-A (ConA), a well-known *in vitro* inducer of MT1-MMP [33, 34] (Fig. 2A) as well as of inflammation [35, 36] and autophagy [37, 38], in the presence or absence of eight different catechins. We found that EGCG and CG were the most potent



**Fig. 3.** Impact of catechins on Concanavalin-A-induced proMMP-2 activation in U87 glioblastoma cells. Serum-starved U87 glioblastoma cells were treated with 30  $\mu$ g/ml ConA for 24 h in the presence of 30  $\mu$ M of each of either the ungalloylated catechins (C, GC, EC, EGC) or with galloylated catechins (CG, GCG, ECG, EGCG). A) Conditioned media were harvested upon treatment and gelatin zymography performed as described in the [Materials and methods](#) section. B) Scanning densitometry of the zymograms was used to quantify the extent of ConA-mediated proMMP-2 activation.

catechins to inhibit ConA-mediated induction of MT1-MMP (Fig. 2B). A slight non-statistically significant inhibitory effect (12–15%) was also observed with GCG, ECG, EC, and C (Fig. 2B). When ConA-mediated induction of the inflammation and endoplasmic reticulum stress biomarker GRP78 expression was monitored (Fig. 2C), we found that EGCG, GCG, and CG were the most potent inhibitory catechins (Fig. 2D). Finally, we further monitored the impact of catechins upon ConA-mediated proMMP-2 activation (Fig. 3A), a process believed to require the formation of a ternary MT1-MMP/TIMP-2/proMMP-2 complex [39]. We found that EGCG, ECG and GCG were the most efficient catechins to prevent proMMP-2 activation as assessed by zymography of the respective condition media harvested (Fig. 3B). Collectively, we conclude that only those catechins specifically bearing the galloyl moiety efficiently altered either ConA-mediated intracellular signaling that regulates MT1-MMP and GRP78 expression, or MT1-MMP-mediated activation of proMMP-2 within the extracellular compartment of U87 glioblastoma cells. Whether any of these galloylated catechins could directly bind to MT1-MMP or to its interactors was next assessed.

### 2.3. Binding assessment of galloylated catechins to MT1-MMP and its interactors using SPR

In order to assess the biophysical properties (capacity and affinity to bind to immobilized proteins) of galloylated catechins, we hypothesized that they could directly target MT1-MMP or some of its interactors.


Thus, through SPR biosensor technology, we first evaluated the binding of four galloylated catechins to MT1-MMP immobilized on CM5 chips. Representative sensograms show that the four tested galloylated catechins significantly interacted with MT1-MMP, with EGCG demonstrating the highest level of binding among them (Fig. 4A). In sharp contrast, none of the tested ungalloylated catechins demonstrated significant interaction with MT1-MMP (sensograms not shown, refer to Kd constants in Fig. 5). When catechin binding was evaluated onto immobilized MMP-2 (Fig. 4B) or onto immobilized TIMP-2 (Fig. 4C) proteins, we observed that the galloylated catechins again targeted significantly those MT1-MMP interactors that collectively contribute to the *in vivo* formation of the MT1-MMP/MMP-2/TIMP-2 ternary complex. Interestingly, MTCBP-1 was also found to significantly be targeted by galloylated catechins (Fig. 4D), as well as the MT1-MMP cell surface substrate LRP-1 (Fig. 4E). Collectively, these observations suggest that potential hierarchical catechin binding processes could potentiate the combined actions of those galloylated catechins. Whether, their binding interferes sequentially with either of these interactors during the formation of the ternary complex remains to be determined.

### 3. Discussion


In this study, we assessed for the first time the direct biophysical binding capacities of green tea-derived catechins at physiological concentrations to MT1-MMP and to MT1-MMP interactors. Our study further emphasizes on the importance of the galloyl moiety, which affects the *in vitro* interacting ability of catechins towards MT1-MMP-mediated proMMP-2 activation processes. In addition, we ranked the catechins according to their structures and binding affinities towards MT1-MMP and MT1-MMP interactors (Fig. 5). Such affinity ranking suggests a hierarchical targeting from the catechins tested and further confirms their potential synergistic molecular action as they are found in food, and explain their pleiotropic anticancer properties against cell signaling functions.

Aside from its canonical role in ECM proteolysis, targeting strategies recently rather aim at altering MT1-MMP's involvement in crucial intracellular signal transduction that control several processes related to cell mobilization and survival [40–42]. As such, it was demonstrated that, as a consequence of ConA-mediated MT1-MMP activation, sequential Src kinase and JAK/STAT3 signaling were required to upregulate CSF-2 and CSF-3 transcription [20]. In that study, the anti-angiogenic EGCG was able to abrogate both ConA- and MT1-MMP-induced JAK/STAT signaling, which effect adds-up to EGCG's pleiotropic biophysical properties. Catechins do not behave exactly as synthetic drugs since they are polytarget molecules given their final effect is due to multiple elements adding up. Direct physical interaction between catechins and membrane-imbedded molecules may, therefore, only represent part of their chemopreventive effects as, for instance, destabilization of lipid rafts or changes in membrane mechanics have recently been inferred [43].

Since its discovery, MT1-MMP has been extensively investigated and emerged among the best characterized MMPs. MT1-MMP is involved in various physiological and pathological processes such as wound healing, bone development, angiogenesis, inflammation, cancer invasion and metastasis [44]. Formation of a ternary MMP-2/TIMP-2/MT1-MMP complex at the cell surface is now a well-recognized mechanism to trigger ECM hydrolysis [45, 46], and MT1-MMP primary functions immediately outside the cell surface [47] believed to drive signaling either from ECM adhesion molecules or in response to chemokines [47, 48]. Given that all three molecules, MMP-2, TIMP-2 and MT1-MMP, have demonstrated the capacity to interact with galloylated catechins, a plausible mechanism of action of these catechins may be, prior to extracellular complexation of MMP-2/TIMP-2/MT1-MMP, to hierarchically bind to them and respectively trigger conformational changes in their structure that would alter ability to lead to ECM degradation or to relay intracellular signals. To validate the latter, one



**Fig. 4.** Binding assessment of catechins to MT1-MMP and its interactors by SPR. Recombinant A) MT1-MMP, B) MMP-2, C) TIMP-2, D) MTCBP-1, or E) LRP1-cluster IV (LRP1-C4) were immobilized on CM5 sensor chips and increasing amounts (0–100  $\mu$ M) of different gallated catechins assessed for interaction by SPR as described in the [Materials and methods](#) section. Representative sensograms are shown.



**Fig. 5.** Kd constants and catechins affinity ranking towards MT1-MMP interactors. Some of recombinant MT1-MMP interactors were immobilized on CM5 sensor chips and increasing amounts (0–100  $\mu$ M) of different catechins assessed for interaction by SPR as described in the [Materials and methods](#) section. A) Kd constants were derived from representative sensograms, and B) affinity ranking towards the immobilized proteins depicted from catechins with low affinity to high affinity catechins. The gallated catechins were grouped into shadowed grey.

would need a complex structure-to-function study with MT1-MMP deletion mutants within its catalytic, hemopexin, and hinge domains all believed to recognize, anchor, and catalyze proMMP to MMP activation. Tentative modeling studies of gallated catechins interaction with MT1-MMP, proMMP-2 and MMP-2 were recently reported and some predicted residues highlighted [23b]. The relevance of these residues in gallated catechins binding still awaits confirmation through site-directed mutagenesis studies.

Our current study also sheds light on the emerging importance of cell surface modulators such as the naturally occurring plant lectin Concanavalin-A (ConA). Such lectin is used by the pharmaceutical industry as part of a reliable *in vitro* cell functional assay for studying biological systems ranging from mitogenicity to pro-inflammatory cytokine production [49, 50]. Given the recent use of the lectin ConA, a potent Toll-Like receptors TLR-2 and TLR-6 agonist [20], our study thus supports the potential green tea catechins-mediated targeting of existing crosstalk between TLRs and cancer [51], angiogenesis [52] and inflammation [53]. Interestingly, ConA is well known to also induce MT1-MMP, the expression of which has also been documented in all the above-regulated processes, similarly to TLR involvement [31, 54]. Our current cellular and acellular approaches imply that EGCG inhibits both ConA- and MT1-MMP-mediated signaling. In support of this, EGCG was already described as inhibiting TLR-2 and TLR-4 signaling [55, 56], as well as the signaling that leads to diminished MT1-MMP gene expression, and that alter signaling cascades that lead to Src and STAT3 phosphorylation [20, 57]. Besides its impact on cancer progression and angiogenesis, catechins-mediated inhibition of MT1-MMP-regulated gene transcription seems to also be among the functions of catechins that may impact on the expression of biomarkers in autophagy [37] as well as in neuroinflammation [58].

Furthermore, the *in vitro* targeting efficacy of EGCG was recently investigated on the NF- $\kappa$ B-mediated transcriptional regulation of a panel of 89 biomarkers associated with promyelocytic HL-60 differentiation into macrophages. NF- $\kappa$ B-mediated signaling during HL-60 macrophage differentiation was reversed by EGCG, in part through reduced I $\kappa$ B phosphorylation, and led to the inhibition of moderately-to-highly expressed NF- $\kappa$ B gene targets among which the matrix metalloproteinase (MMP)-9 and the cyclooxygenase (COX)-2 [59]. Interestingly, green tea catechins containing a galloyl group in the 3' position have also been shown to inhibit tissue factor-induced thrombin generation [60], and to differentially regulate platelet aggregation [61]. Noteworthy, whether the 67-kDa laminin receptor (67LR), which

is believed to be the EGCG cell surface receptor [62], provides the specificity and transduces the effects of the other catechins containing the galloyl group remains to be confirmed. In light of our results, it is however tempting to hypothesize that the interaction between the galloyl groups in the 3' position of catechins with the cell surface 67LR would further account for specific catechins transport, clearance and plasmatic half-life, or downstream signaling modulation.

In conclusion, provided that we report the affinity constant values of EGCG towards MT1-MMP and its interactors to closely approximate its reported plasmatic concentrations of  $\sim$ 1  $\mu$ M [63, 64], with optimal pharmacological effects achieved at 30  $\mu$ M, our study puts emphasis on strategies that could aim at targeting MT1-MMP-mediated proangiogenic and immunomodulatory functions of brain cancer cells. We provide the first biophysical evidence that one such strategy may also support the combined chemopreventive properties of diet-derived gallated catechins which pharmacological targeting of the MT1-MMP extracellular and intracellular signaling functions could decrease brain tumor invasiveness.

## 4. Materials and methods

### 4.1. Materials

Sodium dodecylsulfate (SDS) and bovine serum albumin (BSA) were purchased from Sigma (Oakville, ON). Cell culture media was obtained from Invitrogen (Burlington, ON). Electrophoresis reagents were purchased from Bio-Rad (Mississauga, ON). The enhanced chemiluminescence (ECL) reagents were from Amersham Pharmacia Biotech (Baie d'Urfé, QC). Micro bicinchoninic acid protein assay reagents were from Pierce (Rockford, IL). The rabbit polyclonal antibody against GRP78 was from Santa Cruz Biotechnology (SC-13968, Dallas, TX). The rabbit polyclonal antibody against MT1-MMP was from Chemicon (AB8102, Temecula, CA). Horseradish peroxidase-conjugated donkey anti-rabbit and anti-mouse IgG secondary antibodies were from Jackson ImmunoResearch Laboratories (West Grove, PA). All other reagents, including the green tea-derived catechins tested, were from Sigma-Aldrich Canada. Purity of the catechins tested is as follows: (-)-Catechin (C0567,  $\geq$ 97% (HPLC)), (-)-Gallocatechin (G6657,  $\geq$ 98% (HPLC)), (-)-Epicatechin (E4018,  $\geq$ 98% (HPLC)), (-)-Epigallocatechin (E3768,  $\geq$ 95% (HPLC)), (-)-Catechin gallate (C0692,  $\geq$ 98% (HPLC)), (-)-Gallocatechin gallate (G6782,  $\geq$ 98% (HPLC)), (-)-Epicatechin gallate (E3893,  $\geq$ 98% (HPLC)), (-)-Epigallocatechin gallate (50,299,  $\geq$ 97% (HPLC)).

#### 4.2. Cell culture

The human U87 glioblastoma cell line was purchased from American Type Culture Collection (Manassas, VA) and maintained in Eagle's Minimum Essential Medium containing 10% (v/v) calf serum (HyClone Laboratories, Logan, UT), 1 mM sodium pyruvate, 2 mM glutamine, 100 units/ml penicillin and 100 mg/ml streptomycin. Cells were incubated at 37 °C with 95% air and 5% CO<sub>2</sub>.

#### 4.3. Immunoblotting procedures

Cells were lysed in a buffer containing 1 mM each of NaF and Na<sub>3</sub>VO<sub>4</sub>, and proteins from control and treated cells were separated by SDS–polyacrylamide gel electrophoresis (PAGE). After electrophoresis, proteins were electrotransferred to polyvinylidene difluoride membranes which were then blocked for 1 h at room temperature with 5% non-fat dry milk in Tris-buffered saline (150 mM NaCl, 20 mM Tris-HCl, pH 7.5) containing 0.1% Tween-20 (TBST). Membranes were further washed in TBST and incubated with primary antibodies (1/1000 dilution) in TBST containing 3% BSA and 0.05% Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub>. The primary antibody was removed by washing with TBST, followed by a 1 h incubation with horseradish peroxidase-conjugated anti-mouse IgG (1/5000 dilution) in TBST containing 5% non-fat dry milk. Immunoreactive material was visualized by enhanced chemiluminescence (Amersham Biosciences, Baie d'Urfé, QC).

#### 4.4. Gelatin zymography

Gelatin zymography was used to assess the extent of proMMP-2 gelatinolytic activity and activation status as previously described [34]. Briefly, an aliquot (20 µl) of the culture medium was suspended in a loading dye (62.5 mM Tris HCl pH 6.8; 10% glycerol; 2% SDS; 0.00625% Bromophenol Blue) and subjected to SDS-PAGE in a gel containing 0.1 mg/ml gelatin, a substrate that is efficiently hydrolyzed by proMMP-2 and MMP-2. The gels were then incubated in 2.5% Triton X-100 and rinsed in nanopure distilled H<sub>2</sub>O. Gels were further incubated at 37 °C for 20 h in 20 mM NaCl, 5 mM CaCl<sub>2</sub>, 0.02% Brij-35, 50 mM Tris-HCl buffer, pH 7.6, then stained with 0.1% Coomassie Brilliant blue R-250 and destained in 10% acetic acid, 30% methanol in H<sub>2</sub>O. Gelatinolytic activity was detected as unstained bands on a blue background.

#### 4.5. Surface plasmon resonance (SPR) analysis

SPR analyses were performed using a Biacore T200 instrument (GE Healthcare). LRP-cluster IV, TIMP-2, MMP-2, MT1-MMP, and MTCBP-1 recombinant proteins (Fitzgerald industries international, Acton, MA) were immobilized on a carboxymethylated dextran CM5 sensor chip (GE Healthcare) using an amine-coupling strategy. Briefly, the sensor chip surface was activated with a 1:1 mixture of *N*-hydroxysuccinimide and 3-(*N,N*-dimethylamino)-propyl-*N*-ethylcarbodiimide. Recombinant protein solutions (20 µg/ml) were injected at a flow rate of 10 µl/min using HBS-N running buffer (10 mM HEPES, 150 mM NaCl, pH 7.4) to reach a level of immobilization ranging from 5000 to 10,000 RU. Surfaces (protein and reference) were blocked by the injection of an ethanolamine solution. Binding kinetics of catechins over the immobilized recombinant proteins sensor chip (typically 100–500 nM protein per sensor surface) was evaluated in HBS-N buffer at increased concentrations (6.25 to 100 µM) at a flow rate of 20 µl/min. The sensor chip was regenerated by injecting 20 µl of a 10 mM glycine solution, pH 3. Binding sensograms were obtained by subtraction of the reference flow cell (without protein). Experiments were performed in duplicate and data analysis was performed using the BIA evaluation software package (GE Healthcare) and fit to a one-site Langmuir binding model.

#### 4.6. Statistical data analysis

Data are representative of three or more independent experiments. Statistical significance was assessed using GraphPad Prism 5 software with Student's paired *t*-test. \**P* < .05 was considered significant.

#### Acknowledgments

BA holds an institutional Research Chair in Cancer Prevention and Treatment. This study was supported through funding by the Fondation UQAM.

#### Conflict of interest

The authors declare that they have no conflict of interest.

#### Author contributions

D.D. designed and performed the experiments, analyzed data, wrote the manuscript. M.I. performed the SPR experiments and analyzed data. S.B. designed experiments, analyzed SPR data. S.L. designed experiments, contributed to writing the manuscript. B.A. designed the experiments, analyzed data, and wrote the manuscript.

#### References

- [1] R. Kotecha, A. Takami, J.L. Espinoza, Dietary phytochemicals and cancer chemoprevention: a review of the clinical evidence, *Oncotarget* 7 (32) (2016) 52517–52529.
- [2] A. Kazi, D.M. Smith, K. Daniel, S. Zhong, P. Gupta, M.E. Bosley, Q.P. Dou, Potential molecular targets of tea polyphenols in human tumor cells: significance in cancer prevention, *In Vivo* 16 (6) (2002) 397–403.
- [3] G.B. Maru, R.R. Hudlikar, G. Kumar, K. Gandhi, M.B. Mahimkar, Understanding the molecular mechanisms of cancer prevention by dietary phytochemicals: from experimental models to clinical trials, *World J. Biol. Chem.* 7 (1) (2016) 88–99.
- [4] A.S. Darvesh, A. Bishayee, Chemopreventive and therapeutic potential of tea polyphenols in hepatocellular cancer, *Nutr. Cancer* 65 (3) (2013) 329–344.
- [5] A.H. Rahmani, F.M. Al Shabrimi, K.S. Allemailem, S.M. Aly, M.A. Khan, Implications of green tea and its constituents in the prevention of cancer via the modulation of cell signaling pathway, *Biomed. Res. Int.* 2015 (925640) (2015).
- [6] B. Peter, S. Bosze, R. Horvath, Biophysical characteristics of proteins and living cells exposed to the green tea polyphenol epigallocatechin-3-gallate (EGCG): review of recent advances from molecular mechanisms to nanomedicine and clinical trials. *Eur. Biophys. J.* 46 (1) (2017) 1–24.
- [7] B. Annabi, M.P. Lachambre, N. Bousquet-Gagnon, M. Page, D. Gingras, R. Béliveau, Green tea polyphenol(-)-epigallocatechin 3-gallate inhibits MMP-2 secretion and MT1-MMP-driven migration in glioblastoma cells, *Biochim. Biophys. Acta* 1542 (1–3) (2002) 209–220.
- [8] B. Annabi, M. Bouzeghrane, R. Moumdjian, A. Moghrabi, R. Béliveau, Probing the infiltrating character of brain tumors: inhibition of RhoA/ROK-mediated CD44 cell surface shedding from glioma cells by the green tea catechin EGCG, *J. Neurochem.* 94 (4) (2005) 906–916.
- [9] N.M. Peñaranda Fajardo, C. Meijer, F.A. Kruyt, The endoplasmic reticulum stress/unfolded protein response in gliomagenesis, tumor progression and as a therapeutic target in glioblastoma, *Biochem. Pharmacol.* 118 (2016) 1–8.
- [10] A. Pilorget, V. Berthet, J. Luis, A. Moghrabi, B. Annabi, R. Béliveau, Medulloblastoma cell invasion is inhibited by green tea (-)epigallocatechin-3-gallate, *J. Cell. Biochem.* 90 (4) (2003) 745–755.
- [11] D. Didiano, T. Shalaby, D. Lang, M.A. Grotzer, Telomere maintenance in childhood primitive neuroectodermal brain tumors, *Neuro-Oncology* 6 (1) (2004) 1–8.
- [12] T.C. Chen, W. Wang, E.B. Golden, S. Thomas, W. Sivakumar, F.M. Hofman, S.G. Louie, A.H. Schönthal, Green tea epigallocatechin gallate enhances therapeutic efficacy of temozolomide in orthotopic mouse glioblastoma models, *Cancer Lett.* 302 (2) (2011) 100–108.
- [13] E. Lecumberri, Y.M. Dupertuis, R. Miralbell, C. Pichard, Green tea polyphenol epigallocatechin-3-gallate (EGCG) as adjuvant in cancer therapy, *Clin. Nutr.* 32 (6) (2013) 894–903.
- [14] N. McLaughlin, B. Annabi, M.P. Lachambre, K.S. Kim, J.P. Bahary, R. Moumdjian, R. Béliveau, Combined low dose ionizing radiation and green tea-derived epigallocatechin-3-gallate treatment induces human brain endothelial cells death, *J. Neuro-Oncol.* 80 (2) (2006) 111–121.
- [15] R. Benelli, R. Venè, D. Bisacchi, S. Garbisa, A. Albini, Anti-invasive effects of green tea polyphenol epigallocatechin-3-gallate (EGCG), a natural inhibitor of metallo and serine proteases, *Biol. Chem.* 383 (1) (2002) 101–105.
- [16] S. Lamy, D. Gingras, R. Béliveau, Green tea catechins inhibit vascular endothelial growth factor receptor phosphorylation, *Cancer Res.* 62 (2) (2002) 381–385.
- [17] N. Oku, M. Matsukawa, S. Yamakawa, T. Asai, S. Yahara, F. Hashimoto, T. Akizawa, Inhibitory effect of green tea polyphenols on membrane-type 1 matrix

- metalloproteinase, MT1-MMP, *Biol. Pharm. Bull.* 26 (9) (2003) 1235–1238.
- [18] I. Dell'Aica, M. Donà, L. Sartor, E. Pezzato, S. Garbisa, (-)Epigallocatechin-3-gallate directly inhibits MT1-MMP activity, leading to accumulation of nonactivated MMP-2 at the cell surface, *Lab. Invest.* 82 (12) (2002) 1685–1693.
- [19] M. Maeda-Yamamoto, N. Suzuki, Y. Sawai, T. Miyase, M. Sano, A. Hashimoto-Ohta, M. Isemura, Association of suppression of extracellular signal-regulated kinase phosphorylation by epigallocatechin gallate with the reduction of matrix metalloproteinase activities in human fibrosarcoma HT1080 cells, *J. Agric. Food Chem.* 51 (7) (2003) 1858–1863.
- [20] A. Zgheib, S. Lamy, B. Annabi, Epigallocatechin gallate targeting of membrane type 1 matrix metalloproteinase-mediated Src and Janus kinase/signal transducers and activators of transcription 3 signaling inhibits transcription of colony-stimulating factors 2 and 3 in mesenchymal stromal cells, *J. Biol. Chem.* 288 (19) (2013) 13378–13386.
- [21] H. Tachibana, K. Koga, Y. Fujimura, K. Yamada, A receptor for green tea polyphenol EGCG, *Nat. Struct. Mol. Biol.* 11 (4) (2004) 380–381.
- [22] B. Annabi, J.C. Currie, A. Moghrabi, R. Béliveau, Inhibition of HuR and MMP-9 expression in macrophage-differentiated HL-60 myeloid leukemia cells by green tea polyphenol EGCG, *Leuk. Res.* 31 (9) (2007) 1277–1284.
- [23] X. Wang, K.S. Song, Q.X. Guo, W.X. Tian, The galloyl moiety of green tea catechins is the critical structural feature to inhibit fatty-acid synthase, *Biochem. Pharmacol.* 66 (10) (2003) 2039–2047.
- [24] A. Chowdhury, S.K. Nandy, J. Sarkar, T. Chakraborti, S. Chakraborti, Inhibition of pro-/active MMP-2 by green tea catechins and prediction of their interaction by molecular docking studies, *Mol. Cell. Biochem.* 427 (1–2) (2017) 111–122.
- [25] J. Sarkar, S.K. Nandy, A. Chowdhury, T. Chakraborti, S. Chakraborti, Inhibition of MMP-9 by green tea catechins and prediction of their interaction by molecular docking analysis, *Biomed Pharmacother* 84 (2016) 340–347.
- [26] I. Ulasov, R. Yi, D. Guo, P. Sarvaiya, C. Cobbs, The emerging role of MMP14 in brain tumorigenesis and future therapeutics, *Biochim. Biophys. Acta* 1846 (1) (2014) 113–120.
- [27] D. Szklarczyk, A. Franceschini, S. Wyder, K. Forslund, D. Heller, J. Huerta-Cepas, M. Simonovic, A. Roth, A. Santos, K.P. Tsafou, M. Kuhn, P. Bork, L.J. Jensen, C. von Mering, STRING v10: protein-protein interaction networks, integrated over the tree of life, *Nucleic Acids Res.* 43 (Database issue) (2015) D447–452.
- [28] O. Sharabi, J. Shirian, J.M. Shifman, Predicting affinity- and specificity-enhancing mutations at protein-protein interfaces, *Biochem. Soc. Trans.* 41 (5) (2013) 1166–1169.
- [29] K. Brew, H. Nagase, The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity, *Biochim. Biophys. Acta* 1803 (1) (2010) 55–71.
- [30] C. Ries, Cytokine functions of TIMP-1, *Cell. Mol. Life Sci.* 71 (4) (2014) 659–672.
- [31] A.Y. Strongin, Proteolytic and non-proteolytic roles of membrane type-1 matrix metalloproteinase in malignancy, *Biochim. Biophys. Acta* 1803 (1) (2010) 133–141.
- [32] D. Ravishankar, A.K. Rajora, F. Greco, H.M. Osborn, Flavonoids as prospective compounds for anti-cancer therapy, *Int. J. Biochem. Cell Biol.* 45 (12) (2013) 2821–2831.
- [33] B. Annabi, M. Lachambre, N. Bousquet-Gagnon, M. Page, D. Gingras, R. Béliveau, Localization of membrane-type 1 matrix metalloproteinase in caveolae membrane domains, *Biochem. J.* 353 (Pt 3) (2001) 547–553.
- [34] A. Sina, S. Lord-Dufour, B. Annabi, Cell-based evidence for aminopeptidase N/CD13 inhibitor actinonin targeting of MT1-MMP-mediated proMMP-2 activation, *Cancer Lett.* 279 (2) (2009) 171–176.
- [35] N. Akla, J. Pratt, B. Annabi, Concanavalin-A triggers inflammatory response through JAK/STAT3 signaling and modulates MT1-MMP regulation of COX-2 in mesenchymal stromal cells, *Exp. Cell Res.* 318 (19) (2012) 2498–2506.
- [36] M. Desjarlais, J. Pratt, A. Lounis, C. Mounier, K. Haidara, B. Annabi, Tetracycline derivative minocycline inhibits autophagy and inflammation in concanavalin-A-activated human hepatoma cells, *Gene Regul. Syst. Bio.* 8 (2014) 63–73.
- [37] J. Pratt, R. Roy, B. Annabi, Concanavalin-A-induced autophagy biomarkers requires membrane type-1 matrix metalloproteinase intracellular signaling in glioblastoma cells, *Glycobiology* 22 (9) (2012) 1245–1255.
- [38] T. Yau, X. Dan, C.C. Ng, T.B. Ng, Lectins with potential for anti-cancer therapy, *Molecules* 20 (3) (2015) 3791–3810.
- [39] K. Holmbeck, P. Bianco, S. Yamada, H. Birkedal-Hansen, MT1-MMP: a tethered collagenase, *J. Cell. Physiol.* 200 (1) (2004) 11–19.
- [40] B. Annabi, S. Thibeault, Y.T. Lee, N. Bousquet-Gagnon, N. Eliopoulos, S. Barrette, J. Galipeau, R. Béliveau, Matrix metalloproteinase regulation of sphingosine-1-phosphate-induced angiogenic properties of bone marrow stromal cells, *Exp. Hematol.* 31 (7) (2003) 640–649.
- [41] B. Annabi, S. Thibeault, R. Moudjdjian, R. Béliveau, Hyaluronan cell surface binding is induced by type I collagen and regulated by caveolae in glioma cells, *J. Biol. Chem.* 279 (21) (2004) 21888–21896.
- [42] M. Meriane, S. Duhamel, L. Lejeune, J. Galipeau, B. Annabi, Cooperation of matrix metalloproteinases with the RhoA/Rho kinase and mitogen-activated protein kinase kinase-1/extracellular signal-regulated kinase signaling pathways is required for the sphingosine-1-phosphate-induced mobilization of marrow-derived stromal cells, *Stem Cells* 24 (11) (2006) 2557–2565.
- [43] T. Matsuzaki, H. Ito, V. Chevyreva, A. Makky, S. Kaufmann, K. Okano, N. Kobayashi, M. Suganuma, S. Nakabayashi, H.Y. Yoshikawa, M. Tanaka, Adsorption of galloyl catechin aggregates significantly modulates membrane mechanics in the absence of biochemical cues, *Phys. Chem. Chem. Phys.* 19 (30) (2017) 19937–19947.
- [44] B. Bauvois, Transmembrane proteases in cell growth and invasion: new contributors to angiogenesis? *Oncogene* 23 (2) (2004) 317–329.
- [45] M.M. Bernardo, R. Fridman, TIMP-2 (tissue inhibitor of metalloproteinase-2) regulates MMP-2 (matrix metalloproteinase-2) activity in the extracellular environment after pro-MMP-2 activation by MT1 (membrane type 1)-MMP, *Biochem. J.* 374 (Pt 3) (2003) 739–745.
- [46] H. Kolkenbrock, A. Hecker-Kia, D. Orgel, N. Ulbrich, H. Will, Activation of progelatinase A and progelatinase A/TIMP-2 complex by membrane type 2-matrix metalloproteinase, *Biol. Chem.* 378 (2) (1997) 71–76.
- [47] N.M. Moss, Y.I. Wu, Y. Liu, H.G. Munshi, M.S. Stack, Modulation of the membrane type 1 matrix metalloproteinase cytoplasmic tail enhances tumor cell invasion and proliferation in three-dimensional collagen matrices, *J. Biol. Chem.* 284 (30) (2009) 19791–19799.
- [48] P. Gonzalo, V. Moreno, B.G. Gálvez, A.G. Arroyo, MT1-MMP and integrins: hand-to-hand in cell communication, *Biofactors* 36 (4) (2010) 248–254.
- [49] R.A. Ferriz-Martínez, I.C. Torres-Artega, A. Blanco-Labra, T. García-Gasca, The role of plant lectins in cancer treatment, *Nova Science* (2010) 71–89.
- [50] J.M. Kanellopoulos, S. De Petris, G. Leca, M.J. Crumpton, The mitogenic lectin from *Phaseolus vulgaris* does not recognize the T3 antigen of human T lymphocytes, *Eur. J. Immunol.* 15 (5) (1985) 479–486.
- [51] N. Goutagny, Y. Estornes, U. Hasan, S. Lebecque, C. Caux, Targeting pattern recognition receptors in cancer immunotherapy, *Target. Oncol.* 7 (1) (2012) 29–54.
- [52] K. Grote, H. Schütt, B. Schieffer, Toll-like receptors in angiogenesis, *Sci. World J.* 11 (2011) 981–991.
- [53] Y. Kong, Y. Le, Toll-like receptors in inflammation of the central nervous system, *Int. Immunopharmacol.* 11 (10) (2011) 1407–1414.
- [54] A.G. Arroyo, L. Genís, P. Gonzalo, S. Matías-Román, A. Pollán, B.G. Gálvez, Matrix metalloproteinases: new routes to the use of MT1-MMP as a therapeutic target in angiogenesis-related disease, *Curr. Pharm. Des.* 13 (17) (2007) 1787–1802.
- [55] E.B. Byun, H.G. Choi, N.Y. Sung, E.H. Byun, Green tea polyphenol epigallocatechin-3-gallate inhibits TLR4 signaling through the 67-kDa laminin receptor on lipopolysaccharide-stimulated dendritic cells, *Biochem. Biophys. Res. Commun.* 426 (4) (2012) 480–485.
- [56] E.H. Byun, T. Omura, K. Yamada, H. Tachibana, Green tea polyphenol epigallocatechin-3-gallate inhibits TLR2 signaling induced by peptidoglycan through the polyphenol sensing molecule 67-kDa laminin receptor, *FEBS Lett.* 585 (5) (2011) 814–820.
- [57] P.A. Eisenach, C. Roghi, M. Fogarasi, G. Murphy, W.R. English, MT1-MMP regulates VEGF-A expression through a complex with VEGFR-2 and Src, *J. Cell Sci.* 123 (23) (2010) 4182–4193.
- [58] A. Sina, S. Proulx-Bonneau, A. Roy, L. Poliquin, J. Cao, B. Annabi, The lectin concanavalin-A signals MT1-MMP catalytic independent induction of COX-2 through an IKKgamma/NF-kappaB-dependent pathway, *J. Cell Commun. Signal.* 4 (1) (2010) 31–38.
- [59] A. Vézina, R. Chokor, B. Annabi, EGCG targeting efficacy of NF-κB downstream gene products is dictated by the monocytic/macrophage differentiation status of promyelocytic leukemia cells, *Biochem. Immunol. Immunother.* 61 (12) (2012) 2321–2331.
- [60] G. Cabrini, V. Bezzeri, I. Mancini, E. Nicolis, M.C. Dececchi, A. Tamanini, I. Lampronti, L. Piccagli, N. Bianchi, M. Borgatti, R. Gambari, Targeting transcription factor activity as a strategy to inhibit pro-inflammatory genes involved in cystic fibrosis: decoy oligonucleotides and low-molecular weight compounds, *Curr. Med. Chem.* 17 (35) (2010) 4392–4404.
- [61] P. Bamorough, M.A. Morse, K.P. Ray, Targeting IKKβ for the treatment of rheumatoid arthritis, *Drug News Perspect.* 23 (8) (2010) 483–490.
- [62] S. Chen, Natural products triggering biological targets—a review of the anti-inflammatory phytochemicals targeting the arachidonic acid pathway in allergy asthma and rheumatoid arthritis, *Curr. Drug Targets* 12 (3) (2011) 288–301.
- [63] K. Umegaki, A. Sugisawa, K. Yamada, M. Higuchi, Analytical method of measuring tea catechins in human plasma by solid phase extraction and HPLC with electrochemical detection, *J. Nutr. Sci. Vitaminol.* 47 (6) (2001) 402–408.
- [64] C.S. Yang, L. Chen, M.J. Lee, D. Balentine, M.C. Kuo, S.P. Schantz, Blood and urine levels of tea catechins after ingestion of different amounts of green tea by human volunteers, *Cancer Epidemiol. Biomark. Prev.* 7 (4) (1998) 351–354.